• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Lexeo Therapeutics, Inc. - Common Stock (NQ: LXEO )

    10.40 +2.71 (+35.31%)
    Streaming Delayed Price Updated: 9:49 AM EST, Nov 13, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Lexeo Therapeutics, Inc. - Common Stock

    Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
    From Lexeo Therapeutics
    Via GlobeNewswire
    Lexeo Therapeutics to Participate in Upcoming Investor Conferences
    From Lexeo Therapeutics
    Via GlobeNewswire
    Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
    From Lexeo Therapeutics
    Via GlobeNewswire
    Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy
    From Lexeo Therapeutics
    Via GlobeNewswire
    Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
    Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP with participation from new and existing investors including RA Capital Management, Surveyor... 
    From Lexeo Therapeutics
    Via GlobeNewswire
    Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
    From Lexeo Therapeutics
    Via GlobeNewswire
    Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing
    Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP, with participation from new and existing investors including RA Capital Management, Surveyor... 
    From Lexeo Therapeutics
    Via GlobeNewswire
    Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments
    From Lexeo Therapeutics
    Via GlobeNewswire
    Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    From LEXEO Therapeutics
    Via GlobeNewswire
    Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
    From LEXEO Therapeutics
    Via GlobeNewswire
    Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights
    From LEXEO Therapeutics
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.